Factor | Perrin.Guyomard2020 (40000)

No DOI

AMU Policy Changes: Incentive Tools to Reduce AMU of Critically Important Antimicrobials (CIAs) & Ban of Preventive Use of CIAs

Turkey | Not Specified

6

Description

Before (2014) vs after (2018) incentive tools for reducing AMU of critically important antimicrobials, i.e. prohibition on discounts, rebates, reductions (in effect Jan 1 2015) & ban of preventive CIA use (in effect 2016). Non-wild-type (ECOFF) considered

Resistance Outcomes

Resistance Microbe Outcome
Ciprofloxacin
/
Campylobacter jejuni
See: Figure 2 AMR+ (%) AMR- (%) Total (n)
2018: AMU reduction incentive tools and preventive CIA use ban in place 55.68 183
2014: No AMU reduction incentive tools 48.20 174
Ciprofloxacin
/
Campylobacter jejuni
See: Section 4.2 (pg. 3, para. 5) AMR+ (%) AMR- (%) Total (n)
2018: AMU reduction incentive tools and preventive CIA use ban in place 63.00 183
2014: No AMU reduction incentive tools 56.00 174
Ciprofloxacin
/
Escherichia coli
See: Section 4.3 (pg. 3, para. 6) AMR+ (%) AMR- (%) Total (n)
2018: AMU reduction incentive tools and preventive CIA use ban in place 15.90 214
2014: No AMU reduction incentive tools 21.30 239
Nalidixic Acid
/
Escherichia coli
See: Supplementary Table 1 AMR+ (%) AMR- (%) Total (n)
2018: AMU reduction incentive tools and preventive CIA use ban in place 12.60 214
2014: No AMU reduction incentive tools 20.10 239
Erythromycin
/
Campylobacter jejuni
See: Section 4.2 (pg. 3, para. 5) AMR+ (n) AMR- (n) Total (n)
2018: AMU reduction incentive tools and preventive CIA use ban in place 0 183
2014: No AMU reduction incentive tools 1 174
Gentamicin
/
Campylobacter jejuni
See: Section 4.2 (pg. 3, para. 5) AMR+ (n) AMR- (n) Total (n)
2018: AMU reduction incentive tools and preventive CIA use ban in place 0 183
2014: No AMU reduction incentive tools 1 174